Spots Global Cancer Trial Database for hepatocellular carcinoma (hcc)
Every month we try and update this database with for hepatocellular carcinoma (hcc) cancer trials from around the world to help patients and their families find trials that might be right for them.
We offer this 100% free of charge and do not endorse any of the trials listed here, we hope it helps you or a loved one.
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
| Study title | NCT ID | Conditions | Interventions | Eligibility | Organization | Link |
|---|---|---|---|---|---|---|
| Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant | NCT03960008 | Hepatocellular ... HCC | Stereotactic Bo... Trans-Arterial ... Doxorubin | 18 Years - | Lahey Clinic | |
| CVM-1118 in Combination With Nivolumab for Unresectable Advanced Hepatocellular Carcinoma | NCT05257590 | Hepatocellular ... Advanced Cancer | Nivolumab Injec... CVM-1118 | 18 Years - | TaiRx, Inc. | |
| Liver Cancer Registry Platform | NCT04510740 | Hepatocellular ... Cholangiocarcin... | Physician's cho... | 18 Years - | iOMEDICO AG | |
| A Trial to Evaluate the Safety and Efficacy of the Combination of the Oncolytic Immunotherapy Pexa-Vec With the PD-1 Receptor Blocking Antibody Nivolumab in the First-line Treatment of Advanced Hepatocellular Carcinoma (HCC) | NCT03071094 | Hepatocellular ... | Pexastimogene D... Nivolumab | 18 Years - | Transgene | |
| Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis | NCT02794805 | Hepatocellular ... | ¹³C-Octanoate B... | 18 Years - | Meridian Bioscience, Inc. | |
| A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | NCT04639180 | Hepatocellular ... | Camrelizumab Rivoceranib (Ap... | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| A Phase 2 Study of Brivanib in Chinese Patients With Previously Treated Advanced HCC | NCT03516071 | Hepatocellular ... | Brivanib 800 mg... Brivanib 400 mg... | 18 Years - 75 Years | Zai Lab (Hong Kong), Ltd. | |
| A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer | NCT06345001 | Hepatocellular ... | BAY3630942 BAY3547922 | 18 Years - | Bayer | |
| Phase 3 Study of Tislelizumab Versus Sorafenib in Participants With Unresectable HCC | NCT03412773 | Hepatocellular ... | Tislelizumab Sorafenib | 18 Years - | BeiGene | |
| A Study of DC-CIK to Treat Hepatocellular Carcinoma | NCT01821482 | Hepatocellular ... | Dendritic and C... | 18 Years - | Guangxi Medical University | |
| Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant | NCT03960008 | Hepatocellular ... HCC | Stereotactic Bo... Trans-Arterial ... Doxorubin | 18 Years - | Lahey Clinic | |
| A First-in-Human Study to Learn About How BAY3630942 is Distributed and Processed Inside the Body When Given After BAY3547922 and How Safe it is in People With Liver Cancer | NCT06345001 | Hepatocellular ... | BAY3630942 BAY3547922 | 18 Years - | Bayer | |
| TACE Plus Atezolizumab/Bevacizumab and I-125 Seeds Brachytherapy for HCC With Branch PVTT | NCT05984511 | Hepatocellular ... Hepatic Portal ... Tumor Thrombus | I-125 Seeds Bra... Transcatheter a... Atezolizumab pl... | 18 Years - 75 Years | Third Affiliated Hospital, Sun Yat-Sen University | |
| A Clinical Study to Compare the Efficacy and Safety of HLX10 in Combination With HLX04 Versus Sorafenib as the First-line Treatment in Patients With Locally Advanced or Metastatic HCC | NCT04465734 | Hepatocellular ... | HLX10 HLX04 Sorafenib | 18 Years - 75 Years | Shanghai Henlius Biotech | |
| An Study to Evaluate the Safety and Efficacy of Copanlisib in Combination With Nivolumab in Patients With Advanced Solid Tumors | NCT03735628 | Non-small Cell ... Head and Neck S... Hepatocellular ... | Copanlisib Nivolumab | 18 Years - | Bayer | |
| Hepatic IA Therapy in Stage B or Limited Stage C Hepatoma (HCC) | NCT04601428 | Hepatocellular ... | IA therapy of H... | 18 Years - | Koo Foundation Sun Yat-Sen Cancer Center | |
| Study in the Treatment of HCC With a Radiopaque (RO) Bead (LC Bead LUMI™) Loaded With Doxorubicin | NCT03452553 | Hepatocellular ... | LC Bead LUMI™ (... | 18 Years - | Boston Scientific Corporation | |
| The Safety and Efficacy of Spherical Microwave Ablation for the Treatment of Malignant Liver Tumors | NCT04044326 | Hepatocellular ... | The Solero Micr... | 20 Years - | National Taiwan University Hospital | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| Phase 1/2 Study Exploring the Safety, Tolerability, and Efficacy of INCAGN01876 Combined With Immune Therapies in Advanced or Metastatic Malignancies | NCT03126110 | Advanced Malign... Metastatic Canc... | INCAGN01876 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | NCT02508467 | Hepatocellular ... | Fisogatinib (BL... | 18 Years - | Blueprint Medicines Corporation | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| The Potential Role of Ga-68-PSMA in Staging, Restaging and Monitoring Response in Primary Liver Cancer: Comparison With F-18-FDG | NCT03138239 | Hepatocellular ... | Ga-68-PSMA scan... | 18 Years - 120 Years | Tel-Aviv Sourasky Medical Center | |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | NCT02178722 | Microsatellite-... Endometrial Can... Head and Neck C... Hepatocellular ... Gastric Cancer Lung Cancer Lymphoma Renal Cell Carc... Ovarian Cancer Solid Tumors UC (Urothelial ... Melanoma Bladder Cancer Triple Negative... | MK-3475 INCB024360 | 18 Years - | Incyte Corporation | |
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| Efficacy of Loco-regional Treatment for Hepatocellular Carcinoma Prior to Living Donor Liver Transplantation in Egypt | NCT02990351 | Hepatocellular ... Living Donor Li... | loco regional t... | 18 Years - 65 Years | Ain Shams University | |
| Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study | NCT02188901 | Hepatocellular ... | Sonazoid-enhanc... | 20 Years - | Yonsei University | |
| An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | NCT03144661 | Hepatocellular ... Cholangiocarcin... Esophageal Canc... Nasopharyngeal ... Ovarian Cancer Solid Tumors | INCB062079 | 18 Years - | Incyte Corporation | |
| The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects | NCT03236649 | Hepatocellular ... | Icaritin Sorafenib Tosyl... | 18 Years - 75 Years | Beijing Shenogen Biomedical Co., Ltd | |
| Annexin A2 as a Novel Diagnostic Marker in Hepatocellular Carcinoma | NCT02541149 | Hepatocellular ... | blood sample | 18 Years - 70 Years | Ain Shams University | |
| A Phase 1 Study of Fisogatinib (BLU-554) in Patients With Hepatocellular Carcinoma | NCT02508467 | Hepatocellular ... | Fisogatinib (BL... | 18 Years - | Blueprint Medicines Corporation | |
| Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer. | NCT01204177 | Carcinoma, Hepa... | BAY86-9766 MEK ... | 18 Years - | Bayer | |
| HMBD-001 in Advanced HER3 Positive Solid Tumours | NCT05057013 | Bladder Cancer Triple Negative... Castration-resi... Cervical Cancer RAS Wild Type C... Endometrial Can... Gastric Cancer Hepatocellular ... Melanoma Non-small Cell ... Oesophageal Can... Ovarian Cancer Pancreatic Canc... Squamous Cell C... | HMBD-001 | 16 Years - | Cancer Research UK | |
| A Study to Estimate Safety and Efficacy of Sorafenib (BAY43-9006) in the Treatment of Hepatocellular Carcinoma | NCT00044512 | Carcinoma, Hepa... | Sorafenib (Nexa... | 18 Years - | Bayer | |
| Contrast (Sonazoid)-Enhanced US as a Screening Tool for Hepatocellular Carcinoma in Cirrhosis: An Exploratory Cross-sectional Study | NCT02188901 | Hepatocellular ... | Sonazoid-enhanc... | 20 Years - | Yonsei University | |
| Assessing BAY86-9766 Plus Sorafenib for the Treatment of Liver Cancer. | NCT01204177 | Carcinoma, Hepa... | BAY86-9766 MEK ... | 18 Years - | Bayer | |
| The Potential Role of Ga-68-PSMA in Staging, Restaging and Monitoring Response in Primary Liver Cancer: Comparison With F-18-FDG | NCT03138239 | Hepatocellular ... | Ga-68-PSMA scan... | 18 Years - 120 Years | Tel-Aviv Sourasky Medical Center | |
| A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE | NCT06040099 | Hepatocellular ... | Durvalumab Bevacizumab Transarterial R... | 18 Years - 130 Years | AstraZeneca | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| A Study to Evaluate Camrelizumab Plus Rivoceranib (Apatinib) as Adjuvant Therapy in Patients With Hepatocellular Carcinoma (HCC) at High Risk of Recurrence After Curative Resection or Ablation | NCT04639180 | Hepatocellular ... | Camrelizumab Rivoceranib (Ap... | 18 Years - | Jiangsu HengRui Medicine Co., Ltd. | |
| Prospective Randomised Study of Doxorubicin in the Treatment of Hepatocellular Carcinoma by Drug-Eluting Bead Embolisation | NCT00261378 | Primary Liver C... | Transarterialch... DC Bead with Do... | 18 Years - | Boston Scientific Corporation | |
| A Study of Ramucirumab (IMC-1121B) Drug Product (DP) and Best Supportive Care (BSC) Versus Placebo and BSC as 2nd-Line Treatment in Participants With Hepatocellular Carcinoma After 1st-Line Therapy With Sorafenib | NCT01140347 | Hepatocellular ... | Placebo Ramucirumab DP ... BSC | 18 Years - | Eli Lilly and Company | |
| A Phase II Open Label Study of BMS-582664 in Locally Advanced or Metastatic Hepatocellular Cancer | NCT00355238 | Hepatocellular ... | brivanib (activ... | 18 Years - | Bristol-Myers Squibb | |
| Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC | NCT04241523 | Hepatocellular ... | Lenvatinib 4 mg... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| Study to Explore the Safety, Tolerability and Efficacy of MK-3475 in Combination With INCB024360 in Participants With Selected Cancers | NCT02178722 | Microsatellite-... Endometrial Can... Head and Neck C... Hepatocellular ... Gastric Cancer Lung Cancer Lymphoma Renal Cell Carc... Ovarian Cancer Solid Tumors UC (Urothelial ... Melanoma Bladder Cancer Triple Negative... | MK-3475 INCB024360 | 18 Years - | Incyte Corporation | |
| Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma | NCT05889949 | Radiomics Hepatocellular ... Transcatheter A... Microvascular I... Multi-kinase In... | Sorafenib Lenvatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| A Study of BMS-986416 With and Without Nivolumab in Select Solid Tumors | NCT04943900 | Advanced Solid ... | BMS-986416 Nivolumab | 18 Years - | Bristol-Myers Squibb | |
| Hepatocellular Carcinoma - Advanced Stage - Sorafenib Trial in Taiwanese Patients | NCT01098760 | Hepatocellular ... | Sorafenib (Nexa... | 18 Years - | Bayer | |
| Study of BGB-A317 in Participants With Previously Treated Unresectable HCC | NCT03419897 | Hepatocellular ... | Tislelizumab | 18 Years - | BeiGene | |
| Correlation Between Sorafenib Plasma Concentrations, Toxicity and Disease Control Rate in Patients Treated by Sorafenib for Hepatocellular Carcinoma | NCT02834546 | Hepatocellular ... | Sorafenib plasm... | 18 Years - | University Hospital, Bordeaux | |
| Liver Cancer Registry Platform | NCT04510740 | Hepatocellular ... Cholangiocarcin... | Physician's cho... | 18 Years - | iOMEDICO AG | |
| FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | NCT02325739 | Hepatocellular ... Solid Malignanc... | FGF401 PDR001 | 18 Years - | Novartis | |
| FGF401 in HCC and Solid Tumors Characterized by Positive FGFR4 and KLB Expression | NCT02325739 | Hepatocellular ... Solid Malignanc... | FGF401 PDR001 | 18 Years - | Novartis | |
| Nivolumab Plus Ipilimumab as Neoadjuvant Therapy for Hepatocellular Carcinoma (HCC) | NCT03510871 | Hepatocellular ... | nivolumab, ipil... | 20 Years - | National Health Research Institutes, Taiwan | |
| An Open-Label Safety and Tolerability Study of INCB062079 in Subjects With Advanced Hepatocellular Carcinoma and Other Malignancies | NCT03144661 | Hepatocellular ... Cholangiocarcin... Esophageal Canc... Nasopharyngeal ... Ovarian Cancer Solid Tumors | INCB062079 | 18 Years - | Incyte Corporation | |
| Prospective Cohort Study of Changes in Circulatory MicroRNA of Resected Hepatocellular Carcinoma | NCT05148572 | Hepatocellular ... | 21 Years - 90 Years | National Cancer Centre, Singapore | ||
| Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | NCT00940225 | Solid Tumors Cancer | Cabozantinib Placebo | 18 Years - | Exelixis | |
| TACE for HCC by TANDEM and Idarubicin | NCT03349957 | Hepatocellular ... | Transarterial c... | 18 Years - | University Hospital, Montpellier | |
| Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | NCT00940225 | Solid Tumors Cancer | Cabozantinib Placebo | 18 Years - | Exelixis | |
| Efficacy and Safety of Lenvatinib as a Conversion Therapy for HCC | NCT04241523 | Hepatocellular ... | Lenvatinib 4 mg... | 18 Years - 75 Years | Shanghai Zhongshan Hospital | |
| IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) | NCT03753659 | Hepatocellular ... | Pembrolizumab Radio Frequency... Microwave Ablat... Brachytherapy Transarterial C... | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| Stereotactic Body Radiation Therapy (SBRT) vs Trans-Arterial Chemoembolization (TACE) as Bridge to Transplant | NCT03960008 | Hepatocellular ... HCC | Stereotactic Bo... Trans-Arterial ... Doxorubin | 18 Years - | Lahey Clinic | |
| Annexin A2 as a Novel Diagnostic Marker in Hepatocellular Carcinoma | NCT02541149 | Hepatocellular ... | blood sample | 18 Years - 70 Years | Ain Shams University | |
| QUILT-3.055: A Study of Combination Immunotherapies in Patients Who Have Previously Received Treatment With Immune Checkpoint Inhibitors | NCT03228667 | Non-Small Cell ... Small Cell Lung... Urothelial Carc... Head and Neck S... Merkel Cell Car... Melanoma Renal Cell Carc... Gastric Cancer Cervical Cancer Hepatocellular ... Microsatellite ... Mismatch Repair... Colorectal Canc... | N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... N-803 + Pembrol... N-803 + Nivolum... N-803 + Atezoli... N-803 + Aveluma... N-803 + Durvalu... | 18 Years - | ImmunityBio, Inc. | |
| Study of Cabozantinib (XL184) in Adults With Advanced Malignancies | NCT00940225 | Solid Tumors Cancer | Cabozantinib Placebo | 18 Years - | Exelixis | |
| Determination of HCC With Octanoate Breath Test vs. MRI Diagnosis | NCT02794805 | Hepatocellular ... | ¹³C-Octanoate B... | 18 Years - | Meridian Bioscience, Inc. | |
| Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC | NCT06294808 | Hepatocellular ... | 21 Years - 80 Years | National Cancer Centre, Singapore | ||
| The Phase III Study of Icaritin Versus Sorafenib in PD-L1 Positive Advanced Hepatocellular Carcinoma Subjects | NCT03236649 | Hepatocellular ... | Icaritin Sorafenib Tosyl... | 18 Years - 75 Years | Beijing Shenogen Biomedical Co., Ltd | |
| A US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepatocellular Carcinoma Amenable to TARE | NCT06040099 | Hepatocellular ... | Durvalumab Bevacizumab Transarterial R... | 18 Years - 130 Years | AstraZeneca | |
| A Multicenter, Open-Label, Phase 3 Trial to Compare the Efficacy and Safety of Lenvatinib (E7080) Versus Sorafenib in First-line Treatment of Participants With Unresectable Hepatocellular Carcinoma | NCT01761266 | Hepatocellular ... | Lenvatinib Sorafenib | 18 Years - | Eisai Inc. | |
| Efficacy and Safety of Concurrent TACE and Sorafenib in Patients With HCC and Extrahepatic Metastasis (COTSOM Study) | NCT02311205 | Hepatocellular ... Metastasis | Conventional Tr... sorafenib | 20 Years - | Asan Medical Center | |
| IMMULAB - Immunotherapy With Pembrolizumab in Combination With Local Ablation in Hepatocellular Carcinoma (HCC) | NCT03753659 | Hepatocellular ... | Pembrolizumab Radio Frequency... Microwave Ablat... Brachytherapy Transarterial C... | 18 Years - | Institut für Klinische Krebsforschung IKF GmbH at Krankenhaus Nordwest | |
| A Study Exploring the Safety and Efficacy of INCAGN01949 in Combination With Immune Therapies in Advanced or Metastatic Malignancies | NCT03241173 | Advanced Malign... | INCAGN01949 Nivolumab Ipilimumab | 18 Years - | Incyte Corporation | |
| Microvascular Invasion for Guiding Treatment of Barcelona Clinic Liver Cancer Stage B Hepatocellular Carcinoma | NCT05889949 | Radiomics Hepatocellular ... Transcatheter A... Microvascular I... Multi-kinase In... | Sorafenib Lenvatinib | 18 Years - 75 Years | Sun Yat-sen University | |
| Predicting Survival After Surgical Resection for the Entire Spectrum of Anatomically Resectable HCC | NCT06294808 | Hepatocellular ... | 21 Years - 80 Years | National Cancer Centre, Singapore | ||
| Study of Safety and Tolerability of PDR001 in Combination With Sorafenib and to Identify the Maximum Tolerated Dose and/or Phase 2 Dose for This Combination in Advanced Hepatocellular Patients | NCT02988440 | Hepatocellular ... | PDR001 Sorafenib | 18 Years - | Novartis | |
| GPC3-targeted CAR-T Cell for Treating GPC3 Positive Advanced HCC | NCT04121273 | Hepatocellular ... | CAR-T cell immu... | 18 Years - 69 Years | The Affiliated Nanjing Drum Tower Hospital of Nanjing University Medical School | |
| INCAGN01876 in Combination With Immune Therapies in Subjects With Advanced or Metastatic Malignancies | NCT03277352 | Advanced Malign... Metastatic Canc... | INCAGN01876 Epacadostat Pembrolizumab | 18 Years - | Incyte Corporation | |
| A Pilot Study of Trans Arterial Chemoembolization (TACE), Followed by Stereotactic Radiation Therapy (SBRT) for Patients With Hepatocellular Carcinoma | NCT01247298 | Hepatocellular ... | Stereotactic Bo... | 19 Years - | University of Alabama at Birmingham | |
| Study on Screening, Verification and Intervention of High-risk Patients With Liver Cancer | NCT05721300 | Hepatocellular ... Chronic Hepatit... | NAs（"Entecavir"... NAs （"Entecavir... | 35 Years - 75 Years | Zhongshan Hospital (Xiamen), Fudan University |
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
